BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/13/2024 8:00:25 AM | Browse: 63 | Download: 223
 |
Received |
|
2024-05-28 15:41 |
|
Peer-Review Started |
|
2024-05-28 15:41 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-07-18 01:01 |
|
Revised |
|
2024-07-24 20:25 |
|
Second Decision |
|
2024-08-06 02:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-08-06 06:28 |
|
Articles in Press |
|
2024-08-06 06:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-08-07 02:35 |
|
Publish the Manuscript Online |
|
2024-08-13 08:00 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
B7 homolog 3 in pancreatic cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dijana Perovic, Marija Dusanovic Pjevic, Vladimir Perovic, Milka Grk, Milica Rasic, Maja Milickovic, Tanja Mijovic and Petar Rasic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Petar Rasic, MD, Surgeon, Department of Abdominal Surgery, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic”, Radoja Dakica 6-8, Belgrade 11000, Serbia. perasrv@yahoo.com |
| Key Words |
B7 homolog 3; Pancreatic cancer; Prognosis; Signaling pathways; Immunotherapy |
| Core Tip |
Mortality rates of pancreatic cancer (PC) indicate that we are facing a severe illness characterized by poor survival outcomes. Despite the improvements achieved in the treatment of other types of cancer, the survival of patients with PC is still disappointing. The B7 homolog 3 (B7-H3) checkpoint molecule seems to be a promising immunotherapeutic target since it plays an important role in the progression and antitumor immunity of various cancers. In this review, we analyze the results of different studies related to the role of B7-H3 in PC and discuss its potential to be used as a target in future therapy. |
| Publish Date |
2024-08-13 08:00 |
| Citation |
<p>Perovic D, Dusanovic Pjevic M, Perovic V, Grk M, Rasic M, Milickovic M, Mijovic T, Rasic P. B7 homolog 3 in pancreatic cancer. <i>World J Gastroenterol</i> 2024; 30(31): 3654-3667</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i31/3654.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i31.3654 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
